Status:
COMPLETED
Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
Lead Sponsor:
Verastem, Inc.
Conditions:
Head and Neck Neoplasm
Prostatic Neoplasm
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase (FAK) inhibitor PF-00562271 in patients with positive Positron Emission Tomography \[PET\] scans due to advanc...
Eligibility Criteria
Inclusion
- Pancreatic, head and neck, and prostatic neoplasms, and patients with non-hematologic malignancies who have tumor appropriate for serial biopsy.
- Adequate organ function, including bilirubin less than 1.5 x ULN, and \[Eastern Cooperative Oncology Group\] ECOG performance status of 0-2.
Exclusion
- Clinically significant gastrointestinal abnormalities, requirement for systemic anticoagulants or potent CYP 3A4 inhibitors, and history of clinically significant cardiac or pulmonary disorders.
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT00666926
Start Date
December 1 2005
End Date
April 1 2009
Last Update
March 21 2013
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Aurora, Colorado, United States, 80045
2
Pfizer Investigational Site
Nashville, Tennessee, United States, 37203
3
Pfizer Investigational Site
East Melbourne, Victoria, Australia, 3002
4
Pfizer Investigational Site
Toronto, Ontario, Canada, M5G 2M9